EMPASHIELD SM 10/100/1000 10'S

About

EMPASHIELD SM 10/100/1000 is a triple-combination medication designed for the comprehensive management of type 2 diabetes mellitus. It combines three distinct mechanisms of action to achieve optimal glycemic control. Empagliflozin, an SGLT2 inhibitor, works by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine and subsequently lowering blood glucose levels. Sitagliptin, a DPP-4 inhibitor, enhances the body's natural ability to lower high blood sugar by increasing the levels of incretin hormones, which stimulate insulin release and decrease glucagon secretion in a glucose-dependent manner. Metformin, a biguanide, primarily reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity in peripheral tissues. This synergistic approach not only helps to significantly reduce HbA1c but also offers additional benefits such as weight management and cardiovascular protection, making it a robust option for patients requiring multifaceted glycemic control.

Uses

• To improve glycemic control in adults with type 2 diabetes mellitus.
• Used as an adjunct to diet and exercise.
• For patients inadequately controlled on metformin, or metformin and a DPP-4 inhibitor, or metformin and an SGLT2 inhibitor.
• May reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.

Directions For Use

Take this medication orally, usually once daily with a meal, as prescribed by your healthcare provider. Swallow the tablet whole with water.

Benefits

• Comprehensive blood glucose control through three distinct mechanisms.
• Significant reduction in HbA1c levels.
• Potential for modest weight loss.
• May offer cardiovascular and renal protective benefits.
• Convenience of a single tablet for multiple therapies.
• Improved insulin sensitivity and reduced glucose production.

Side Effects

• Nausea
• Diarrhea
• Urinary tract infections
• Genital yeast infections
• Abdominal pain
• Headache
• Nasopharyngitis
• Increased urination
• Dizziness
• Joint pain
• Hypoglycemia (when used with insulin or sulfonylureas)
• Lactic acidosis (rare, serious)

Safety Measures

• Alcohol - Limit alcohol intake as it can increase the risk of lactic acidosis, especially with metformin, and may also increase the risk of hypoglycemia.
• Pregnancy - Not recommended during pregnancy, especially in the second and third trimesters, due to potential adverse effects on fetal kidney development. Consult your doctor.
• Breastfeeding - Not recommended during breastfeeding as components may pass into breast milk and could affect the infant. Consult your doctor.
• Liver - Use with caution in patients with liver impairment, particularly with metformin, due to increased risk of lactic acidosis. Not recommended in severe hepatic impairment.
• Kidney - Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²). Dose adjustments are necessary for moderate renal impairment, and empagliflozin efficacy is reduced with declining renal function.
• Lung - Severe acute or chronic lung disease leading to hypoxia can increase the risk of lactic acidosis, especially with metformin. Use with caution.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.